X Curso internacional de avances en Oncología: Investigación y nuevos fármacos

Translated title of the contribution: 10th International course in progress in Oncology: Research and new drugs

Enrique Espinosa Arranz, Manuel Hidalgo, Juan Carlos Lacal Sanjuán, Félix Reyes, M. Luisa García De Paredes, César Picó, Rosario Perona Abellón, K. Polyak

Research output: Contribution to journalArticle

Abstract

This international symposium was hold in Cádiz in November 2002. In the first conference, a classification of anticancer drugs including all the new compounds was proposed. The role of cholino-kinase in oncogenesis was revised, as well as the possibility to use this model in the development of new drugs. The first group of conferences was finished with a speech about how we are investigating with new drugs, considering the limitations of our traditional paradigm. The second group of conferences included a revision of different drugs: monoclonal antibodies, gefitinib, imatinib and Cox-2 inhibitors. The speakers commented on the results of clinical trials and the future investigation with these drugs. Finally, the third block included a revision a techniques in molecular oncology and a speech about the kind of information that we are achieving through the use of these techniques.

Translated title of the contribution10th International course in progress in Oncology: Research and new drugs
Original languageSpanish
Pages (from-to)98-110
Number of pages13
JournalClinical and Translational Oncology
Volume5
Issue number2
StatePublished - Mar 1 2003

Keywords

  • Cholino-kinase
  • Gefitinib
  • Monoclonal imatinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '10th International course in progress in Oncology: Research and new drugs'. Together they form a unique fingerprint.

  • Cite this

    Arranz, E. E., Hidalgo, M., Sanjuán, J. C. L., Reyes, F., De Paredes, M. L. G., Picó, C., Abellón, R. P., & Polyak, K. (2003). X Curso internacional de avances en Oncología: Investigación y nuevos fármacos. Clinical and Translational Oncology, 5(2), 98-110.